Company Continues Nationwide Expansion with Plans to Open Ten State-of-the-Art Fertility Clinics to Support Growing Demand from Employers and Patients Nationwide

NEW YORK, March 2, 2023 — Kindbody, a leading technology-driven fertility clinic network and family-building benefits provider for employers, today announced it raised $100 million in capital from Perceptive Advisors, a leading life sciences investment firm, to support future company growth. The latest financing brings Kindbody’s total equity and debt funding to more than $290 million, and its valuation to $1.8 billion, solidifying its position as the largest women-owned fertility company serving employers and consumers. This financing allows the company to continue to execute on its vision of affordable and accessible fertility care, by adding new clinics in underserved U.S. markets and by investing in operations to further enhance its care model which is designed to deliver industry-leading clinical outcomes.

Kindbody was founded in late 2018 to fix fertility healthcare in the U.S., which is fragmented, inequitable, expensive, and inaccessible to most. Kindbody is the only family-building benefits provider that owns and operates fertility clinics saving employers 25%-30% by contracting directly with them to provide comprehensive virtual and in-person care to their employees. As the direct provider of clinical care, Kindbody is uniquely positioned to provide a seamless continuum of care, decrease cost, improve patient experience, and deliver better health outcomes.

“Infertility is widespread, more common than diseases like cancer or diabetes. Yet, for far too long, high-quality fertility care has been available to only a privileged few,” said Gina Bartasi, Founder and Chairwoman of Kindbody. “With the support of Perceptive Advisors, and our other investors, Kindbody is positioned to deliver on our vision to help everyone realize their dream of becoming a parent by making high-quality fertility care affordable and accessible for all.”

Bartasi continued, “In 2023, Kindbody will sharpen its operations, make strategic acquisitions, and maintain our laser focus on profitable growth.”

Kindbody has grown significantly in the past year. In 2022, the company added 42 large employer clients, including Walmart, and today is the fertility benefits provider for 112 companies, covering more than 2.4 million lives. The company made three strategic acquisitions to accommodate growth. Kindbody acquired Vios Fertility Institute, more than doubling its national clinic footprint; a genomics company, adding genetic testing and carrier screening to its end-to-end care delivery model; and, a gestational surrogacy agency, further expanding its continuum of care. Today, Kindbody owns and operates 31 clinics nationwide with plans to open ten new clinics in 2023 in underserved markets with the greatest demand for affordable, high-quality fertility healthcare.

“This team is unstoppable in their vision to reinvent fertility healthcare,” said Sam Chawla, Portfolio Manager at Perceptive. “Kindbody’s differentiated care delivery model, focused on exceptional patient experience and outcomes at a reduced cost for employers and patients, positions it to meet the urgent need for better fertility healthcare solutions, making Kindbody an attractive opportunity for us.”

Kindbody is a technology-driven fertility clinic network and family-building benefits provider for employers offering virtual and in-person care. Kindbody is the trusted fertility benefits provider for 112 leading employers, covering more than 2.4 million lives. Many thousands more receive their fertility care directly from Kindbody throughout the country at signature clinics, mobile clinics, and partner clinics. As the fertility benefits provider, technology platform, and direct provider of high-quality care, Kindbody delivers a seamless, integrated experience with superior health outcomes at lower cost, making fertility care more affordable and accessible for all. Kindbody has raised $290 million in funding from leading investors including Perceptive Advisors, GV (formerly Google Ventures), RRE Ventures, Claritas Health Ventures, Rock Springs Capital, NFP Ventures, and TQ Ventures. For more information, visit kindbody.com and follow us on Linkedin, Twitter, and Instagram.

Contact:

Margaret Ryan
Kindbody
[email protected]

SOURCE Kindbody

Growth equity fund co-founded by restaurateur Danny Meyer invests in technology platform to bring ‘anticipatory hospitality’ to the world

NEW YORK, March 2, 2023 — SevenRooms, a leading global guest experience and retention platform for the hospitality industry, today announced an investment from Enlightened Hospitality Investments (“EHI”), a strategic growth equity firm affiliated with Union Square Hospitality Group (“USHG”), and acclaimed restaurateur and entrepreneur, Danny Meyer. EHI joins SevenRooms’ prominent roster of hospitality investors including José Andrés, Wolfgang Puck, Michael Mina, Thomas Keller and Jeremy King, and will serve as an industry advisor to the company as it continues to scale.

SevenRooms brings a unique approach to the industry, focused 100% on the operator to help them create more sustainable, profitable businesses, investing in them in the same way they invest in their guests. This approach puts restaurant and hotel F&B brands front and center, enabling their teams to own their guest relationships and data. It also gives hospitality businesses their own marketing engine that ensures a direct connection to guests to enable longevity for the business. By utilizing SevenRooms operators not only build direct relationships with guests to personalize future experiences, but can utilize marketing automation to bring them back to the restaurant directly and more often.

“At EHI, we always pay close attention to transformative tech that advances high touch,” said Danny Meyer, Founder and Executive Chairman of USHG and Co-Founder and Managing Partner at EHI. “Far more than a reservations platform, SevenRooms provides abundant tools to create highly customized guest experiences and equips both restaurant and hotel teams to do what they do best – deliver truly memorable hospitality.”

SevenRooms has redefined hospitality technology as the only end-to-end, data-driven guest experience platform purpose-built to help operators reach diners across all the channels their guests are searching for them. Consumers today no longer rely on a single source or aggregator to find their next favorite restaurant or hotel F&B outlet. It is critical that today’s operators take advantage and have control over all demand channels (first-party, free and paid third-party) that consumers are using to discover and book experiences. This includes channels like Google, Instagram, Facebook, global discovery sites like TripAdvisor, TheFork, Zomato, ReserveOut, OpenRice and Chope, and a restaurant’s own website — all channels SevenRooms integrates into today. By creating a direct pathway from discovery to booking directly on their own channels, operators not only build brand loyalty and drive revenue, but also create a more personalized guest experience.

“We’re thrilled to partner with Danny and EHI, combining their industry-leading expertise with our all-in-one platform as we continue to innovate with them at our table,” said Joel Montaniel, CEO & Founder of SevenRooms. “No matter how the industry has evolved, SevenRooms has always been dedicated and focused on empowering operators with tools for success. Our omnichannel approach, enabling hospitality businesses to meet guests wherever they are, whether through global discovery and booking channels or the operators’ own websites, is the future of this industry.”

SevenRooms operates in more than 75 countries worldwide and has dining, hotel F&B, nightlife and entertainment clients including: MGM Resorts International, Mandarin Oriental Hotel Group, Jumeirah Group, Wolfgang Puck, Michael Mina, Bloomin’ Brands, LDV Hospitality, Zuma, Australian Venue Company, Altamarea Group, The Wolseley Hospitality Group, Live Nation and Topgolf. Over the last three years, SevenRooms’ revenue has grown over 300%, with nearly 1 billion people around the world seated through the platform since 2011.

EHI focuses on investing in high-growth, category-leading companies, with an emphasis on technology that fuels hospitality and guest experiences. The investment will allow SevenRooms’ global technology platform to enable more operators to own their guest data and relationships, deliver exceptional experiences, and boost profitability and repeat business.

For more information on SevenRooms and its platform offering, please visit www.sevenrooms.com.

About SevenRooms

SevenRooms is a guest experience and retention platform that helps hospitality operators create exceptional experiences that drive revenue and repeat business. Trusted by thousands of hospitality operators around the world, SevenRooms powers tens of millions of guest experiences each month across both on- and off-premises. From neighborhood restaurants and bars to international, multi-concept hospitality groups, SevenRooms is transforming the industry by empowering operators to take back control of their businesses to build direct guest relationships, deliver exceptional experiences and drive more visits and orders, more often. The full suite of products includes reservation, waitlist and table management, online ordering, mobile order & pay, review aggregation and marketing automation. Founded in 2011 and venture-backed by Amazon, Comcast Ventures, PSG and Highgate Ventures, SevenRooms has dining, hotel F&B, nightlife and entertainment clients globally, including: MGM Resorts International, Mandarin Oriental Hotel Group, The Cosmopolitan of Las Vegas, Wynn Resorts, Jumeirah Group, Wolfgang Puck, Michael Mina, Bloomin’ Brands, Giordano’s, LDV Hospitality, Zuma, Australian Venue Company, Altamarea Group, AELTC, The Wolseley Hospitality Group, Dishoom, Live Nation and Topgolf. www.sevenrooms.com

About Enlightened Hospitality Investments

Enlightened Hospitality Investments (EHI) is a value-added strategic investor formed to leverage the brands, businesses, and team of Union Square Hospitality Group to identify growth potential and investment opportunities in both internal and outside ventures. EHI partners with portfolio companies to provide strategic direction, operational experience, increased visibility, and access to relationships, resulting in significant value creation for all stakeholders. For additional information on Enlightened Hospitality Investments, please visit www.ehi.fund.

Media Contact:

Bianca Esmond
Director, Brand Marketing
[email protected]

SOURCE SevenRooms

GHENT, Belgium, March 2, 2023  — Belgian legal tech company Henchman announced it has closed a $7 million Series A funding round, bringing its total to $10 million to become the industry-leading contract drafting and negotiation solution. The round is led by Adjacent VC and Acton Capital, joined by several business angels, and follows Henchman’s recent GPT-3 integration. The funds will be used to further innovate and expand geographically.

Legal professionals rarely start from a blank sheet of paper when drafting contracts or negotiating details with other parties. They usually reference existing documentation, for which they need to sift through hundreds of old contracts or talk to their colleagues to find suitable precedents that may be relevant to their case. Henchman solves this problem by automatically centralizing past clauses and definitions from any legal team’s contract database (whether law firm or corporate legal department) and delivering them intelligently in lawyers’ familiar Microsoft Word or Outlook environments.

The founders, Jorn Vanysacker, Gilles Mattelin, and Wouter Van Respaille started working on the solution during the COVID-pandemic. Henchman has been on a remarkable trajectory since launching in June 2021 and has experienced rapid adoption and growth over the past year: 750% revenue growth, over 100 customers in 15 countries, and a team that grew from 12 to 35 employees.

Henchman helps the lawyer of the future provide added value and expertise. “When everyone was still talking about ChatGPT, we implemented the technology in Henchman,” says Gilles Mattelin, Founder of Henchman. With the AI-based functionality, lawyers can now use Henchman to enrich contracts with new suggestions, translations or grammatical adaptations.

The company intends to use the capital injection to stay ahead of the competition and enter new markets. To make that happen, the company brought some new investors on board: the U.S.-based Adjacent VC, which previously invested in companies such as BeReal and Revolut and the German Acton Capital, which previously funded Clio and Etsy, are taking the lead in this investment round, with participation from several business angels, including Louis Jonckheere & Pieterjan Bouten (founders Showpad), Felix Van de Maele (founder Collibra) and Bram Couvreur (Partner at U.S.-based law firm Cooley).

“After a few reference calls it became clear that Henchman’s power lies within how perfectly the product fits into the legal professionals’ existing workflow. It’s rare to see a SaaS company win international clients this early in its journey, but the teams’ customer obsession is driving great adoption in both Europe and the US. I’m excited to team up as we scale to the next level!” says Nico Wittenborn, Investor at Adjacent VC.

Louis Jonckheere, private investor and founder of Showpad, is optimistic: “The legal profession is entering a new age with AI. I’m very bullish about Henchman’s ability to take a leading role in this transformation. They have the team, technology and traction to become a dominant global player.”

henchman.io

Photo: https://mma.prnewswire.com/media/2013622/Team_Picture.jpg

SOURCE Henchman

Global Competition Offers Opportunity to Make an Impact and Win $25,000

NEW YORK, March 2, 2023 — The “Create the Future” Design Contest (www.createthefuturecontest.com), produced by SAE Media Group and Tech Briefs magazine, is now open for entries through July 1, 2023. The world’s premier engineering design competition invites engineers, entrepreneurs, and students to push the boundaries of innovation and find solutions that benefit society and the economy. Participants are given the opportunity to showcase their ingenuity along with sound design principles for a chance to win a $25,000 grand prize and over $50,000 in total prizes.

Now celebrating its 21^st year, the “Create the Future” Design Contest has attracted more than 15,000 product ideas from innovators in over 100 countries. COMSOL and Mouser Electronics are the platinum sponsors of the contest.

“COMSOL is looking forward to seeing the innovative ideas contestants come up with for this year’s Create the Future design contest,” said Margaret Lemus, vice president of marketing at COMSOL, Inc. “We are grateful for the opportunity to support the contest and wish all participants the best of luck!”

“Advancing technological innovation is at the core of what we do here at Mouser,” said Kevin Hess, Mouser Electronics’ Senior Vice President of Marketing. “We are proud of our longstanding support for the Create the Future Design Contest and the many innovations it has inspired.”

Contestants can enter for free as individuals or teams across seven categories. An independent panel of industry professionals will judge the entries, with category and grand prize winners selected during a live competition this fall in New York City. Website visitors are invited to vote for their favorite entries. For more information, visit http://createthefuturecontest.com.

About COMSOL 
COMSOL is a global provider of modeling and simulation software used by engineers and scientists in all fields of engineering, manufacturing, and scientific research. Its COMSOL Multiphysics® product is a simulation platform for creating and managing physics-based models and simulation applications. COMSOL has 17 offices worldwide and extends its reach with a network of distributors. Visit www.comsol.com. 

About Mouser Electronics
Mouser Electronics, a Berkshire Hathaway company, is an authorized semiconductor and electronic component distributor focused on New Product Introductions from its leading manufacturer partners. Serving the global electronic design engineer and buyer community, the global distributor’s website, mouser.com, is available in multiple languages and currencies and features more than 6.8 million products from over 1,200 manufacturer brands. Mouser offers 27 support locations worldwide to provide best-in-class customer service in local language, currency and time zone. The distributor ships to over 650,000 customers in 223 countries/territories from its 1 million-square-foot, state-of-the-art distribution facilities in the Dallas, Texas, metro area. For more information, visit https://www.mouser.com/.

For Information Contact:
Kaitlyn Sommer
Director of Marketing
SAE Media Group
212-490-3999 ext. 5514
[email protected] 
www.createthefuturecontest.com

Facebook
Twitter
LinkedIn

SOURCE SAE Media Group

Partnership with Curewell Accelerates Growth and Innovation of Best-in-Class Technology for Infusion Providers and Specialty Pharmacies

AUSTIN, Texas and DALLAS, March 2, 2023 — WeInfuse, the premier software and technology platform for infusion therapy and medication delivery in the U.S., announced a significant growth equity investment from Curewell Capital to support the company’s continued expansion and strategic initiatives. The terms of the transaction were not disclosed.

WeInfuse will use the newly-secured funds to invest in its foundational software platform for infusion centers and accelerate its home infusion and specialty pharmacy solutions. To continue delivery of best-in-class modern software solutions to providers of specialty infusion services, Curewell and WeInfuse have formed the Infusion Technology Advisory Council (ITAC), assembling industry leaders from the infusion, specialty pharmacy, and healthcare technology sectors.

As part of the investment, Michael Dal Bello and Ceron Rhee, Partners at Curewell Capital, and George Lazenby, Curewell Senior Advisor and CEO of OrderInsite, will be joining WeInfuse’s board of directors and help lead ITAC. Lazenby brings over 25 years of leadership in healthcare and pharmacy technologies. Prior to founding OrderInsite, a leading provider of cloud-based pharmacy supply chain and investment management software, Lazenby was the CEO of Emdeon (now Change Healthcare), the nation’s largest health information network. Lazenby was previously COO of Medifax EDI, one of the nation’s leading revenue cycle management companies.

“We are very excited to partner with Curewell. Michael, Ceron, and George bring a wealth of experience in the infusion, pharmacy, and healthcare technology space,” said Bryan Johnson, Co-Founder and CEO of WeInfuse. “This partnership will greatly accelerate our product roadmap on all fronts and enable ongoing investment in our foundational medication delivery platform. With Curewell’s extensive infusion experience, we’re confident we’ll provide the industry with the most innovative, capable, and user-friendly solution. Together, our future is bright.”

“WeInfuse’s purpose-built software is a market-leading technology platform that offers clinical infusion providers a truly comprehensive end-to-end workflow solution that ensures accurate and efficient patient intake and scheduling, clinical operations, prior authorization, and payor reimbursement,” said Dal Bello. “WeInfuse’s integrated rules engine enables infusion providers to scale efficiently and expand their therapeutic offerings, increasing revenues with optimal clinical quality.”

Rhee added, “WeInfuse has continually been on the forefront of innovation that benefits stakeholders throughout the infusion industry. We are thrilled to partner with co-founders Bryan Johnson and Reece Norris, along with the entire WeInfuse team, to further accelerate the development of new and existing initiatives and products.”

About WeInfuse

WeInfuse is the premier software and technology provider for infusion therapy and medication delivery in the U.S. The software platform powers over 625 infusion centers across the country. WeInfuse has expanded its platform to include a complete home infusion and specialty pharmacy workflow. WeInfuse software helps organizations operate efficiently, maximize profitability, decrease burnout, and improve clinical outcomes. Its powerful, intuitive features for infusion workflows and a robust reporting and analytics engine help take the confusion out of infusion. For more information, visit weinfuse.com or email [email protected].

About Curewell Capital

Curewell Capital is a growth-oriented investment firm focused on building industry-leading healthcare companies. Drawing upon decades of investment and operating experience in healthcare services, medical devices, pharmaceutical services, and healthcare technology, Curewell Capital partners with owners and management teams leading extraordinary companies that improve patient outcomes, enhance efficiency, and foster innovation. Curewell Capital’s patient capital base provides the ability to invest in minority and majority equity positions with a flexible time horizon. The firm is based in Los Angeles, California.

SOURCE WeInfuse

Fund IV Oversubscribed Due to Support from both New and Existing Investors

DALLAS, March 2, 2023 — Traveller Capital Advisors (“Traveller” or “the Firm”), an investment firm focused on the secondary market acquisition of interests in private equity funds, today announced the successful closing of Traveller Capital Partners IV, LP (“Fund IV” or “the Fund”) with $44 million in capital commitments. Fund IV received commitments from a diverse investor group, including RIAs, family offices and sophisticated high net worth investors.

Traveller is a dedicated and active buyer of private equity fund interests on the secondary market with a focus on small-balance transactions. Since inception, the Firm has acquired approximately 100 LP interests through its first three fund vehicles. Fund IV was oversubscribed, enabling Traveller to expand its pursuit of opportunistic acquisitions of both single LP positions and portfolios of LP positions.

“We are excited by the compelling opportunity set within the smaller end of the secondary market,” commented Drew Crichton, Traveller’s founder. “Many of our investors have been with us for multiple funds, and their long-term perspective and belief in the outlook for our strategy drove a historically strong raise. We are grateful for this level of participation given today’s challenging environment for fundraising in general.”

“We strive to build on our long-term relationships and reputation as an established investor in our target market, helping to create unique sourcing capabilities to identify small-balance interests,” continued Crichton. “This is an area of the market that is less efficient, so relationships certainly matter.”

Traveller seeks to construct portfolios diversified across fund managers, vintages, sectors, strategies, and geographies within the U.S. To date, the Firm has completed two transactions within Fund IV.

About Traveller

Traveller Capital Advisors is a Dallas, Texas-based investment manager focused on the secondary market acquisition of interests in private equity funds. Founded in 2013, Traveller primarily pursues smaller secondary transactions, often mature capital accounts with balances below $2 million. Traveller considers a wide array of US-based strategy types, including buyout, venture capital, credit, and natural resource funds.

Media Contact

ImageArb

214.396.4041

SOURCE Traveller Capital Advisors LLC

Award-Winning Algorithmic Execution Platform Continues Expansion

STAMFORD, Conn., March 2, 2023 — BestEx Research Group LLC, an independent provider of high-performance algorithmic execution solutions for equity, futures and foreign exchange trading, is pleased to announce a $10 million follow-on investment from its existing investors. The investment will allow BestEx Research to accelerate its growth, expanding its global team as it prepares to roll out a differentiated suite of algorithms for FX and enhancements to existing tools for equities and futures.

Since BestEx Research’s Series A funding in 2020, BestEx Research has become a leading independent provider of execution algorithms for equities and global futures to both buy-side firms and banks. Its unique Algorithm Management System (AMS) was recently awarded Best Algorithmic Trading Platform and Best Buy-Side Transaction Cost Analysis (TCA) for equities and futures by Waters Technology. The firm’s average daily trading volume has grown to over $2.1 billion with 25 clients now trading, and the team now includes 35 employees in three offices across the globe. The current funding brings the firm’s valuation to $110 million.

Founder and CEO of BestEx Research Hitesh Mittal, commented, “Constant advancement is in our DNA. Our vision of extreme transparency, modern algo architecture with research-driven design, and careful measurement of outcomes resonates with our customers. To meet their demand, we’re expanding in multiple dimensions to cover additional asset classes and regions and increase the size and scope of our team as we provide exemplary support to users of our products.”

Buy-side firms can access BestEx Research algorithms via most execution management systems (EMS) and order management systems (OMS) with no disruption to their workflow. Sell-side firms can use BestEx Research’s holistic Algorithm Management System (AMS) to build completely custom execution solutions with no coding required, support their clients via web-based dashboard, backtest custom strategies with its realistic exchange simulator, and measure performance with sophisticated transaction cost analysis (TCA). The award-winning platform can be tailored to provide an unconflicted, high-performance trading experience to any customer interested in reducing transaction costs and increasing transparency around execution.

About BestEx Research

BestEx Research Group LLC was founded in 2017 by a team of industry experts in systematic trading. BestEx Research is creating a new category of innovative, broker-neutral solutions that combine sophisticated execution algorithms with a user-friendly dashboard and transaction cost analysis for multiple asset classes. The cloud-based platform is the first independent algorithmic trading solution for equities, futures, and foreign exchange in all markets. BestEx Research algorithms are reducing trading costs for buy-side managers and providing sell-side firms with a seamless trading solution for their clients. For more information on BestEx Research’s mission and products, or to request a product demo, please visit www.bestexresearch.com. Please follow BestEx Research on LinkedIn and Twitter.

Media Contact
Kathryn Berkow
[email protected]

SOURCE BestEx Research

Attio is powerful, highly configurable, real-time and beautifully designed, giving businesses the modern tool they need to grow and scale

SAN FRANCISCO and LONDON, March 2, 2023 — Attio, the company building the CRM of the future, today announced $23.5 million in Series A funding led by Redpoint Ventures, with continued participation from existing investors Balderton Capital and Point Nine. Attio has now secured $31.2 million from both American and European investors. The company will use the funding to accelerate engineering and product development and expand its go-to-market presence globally.

Attio is a radically new type of CRM that empowers companies to achieve what was, up until now, previously impossible for CRMs. With a powerful data model built on cutting-edge, modern architecture, Attio makes it possible for companies to rapidly build a real-time CRM that fits their business’ unique workflows and data structures. This is in contrast to legacy CRMs, which, although offer robust data models, have outdated user experiences, rely on manual data input, and are slow to deploy and configure.

“Attio’s mission is to build a CRM that is not only beautiful and intuitive, but powerful enough to empower businesses to scale. That’s why we’ve spent the last three years building a powerful architecture from scratch specifically for CRM,” said Nicolas Sharp, co-founder, and CEO of Attio. “We’ve seen challenger CRMs come to the market repeatedly with the same proposition: a more straightforward CRM. However, focusing on that alone won’t cut it unless you also build a robust data model to help businesses evolve and scale.”

Attio is now generally available after being in public beta for three months and private beta for just over a year. It has over 2,000 customers in over 100 countries around the world. Current customers include OpenAI, Causal, Pallet, Dopt, On Deck, and Coca-Cola.

Bringing CRM into the Modern Era

CRM is one of the most widely-used B2B technologies in the world. However, it continues to frustrate users because the entire ecosystem is built on archaic architectures that were designed 20 years ago when the speed, scale, and capabilities that businesses require today could not be conceptualized.

As a result, even though legacy CRMs can have incredibly powerful data models, users cannot take full advantage of them due to their slow and complex nature. The most advanced deployments can take years to carry out and the user experiences are clunky and out-of-date.

“Legacy CRM has impressive architectures, but they have an inherent weakness in their foundation. No matter how much they upgrade or rebuild, they remain constrained by the legacy decisions and technology they started with decades ago,” said Alexander Christie, co-founder and CTO of Attio. “With billions of lines of code and over a hundred thousand customers, you cannot move fast to execute on new technologies or customer needs, even with data model rebuilds. That is the reality of scale.”

Meanwhile, no-code CRM solutions on the market today focus on delivering a nicer user experience, but it comes at the expense of the power and functionality companies need to truly scale. Users are essentially stuck between two options: extremely slow, complicated legacy CRMs with a powerful data model or fast, basic CRMs with a simple and rigid data model.

Attio solves this issue by providing a modern CRM with a robust data model that is also completely customizable, fast, intuitive, and easy to use.

Attio: Flexible and Customizable From Day 1 to IPO

Attio is powerful, real-time, multiplayer, and beautifully designed without sacrificing any of the necessary features businesses need to grow and scale.

“Attio is building from the ground up a modern CRM with a composable UX, an extensible data model, and advanced workflows and integrations. It balances ease-of-use with underlying data sophistication to scale with businesses from day 1 to IPO,” said Alex Bard, managing director at Redpoint Ventures and former Salesforce executive. “Legacy CRMs are complex to set up, generally rely on manual input, and are designed primarily to store data, rather than provide insights and intelligence. Attio can be set up nearly instantly and delivers immediate impact to users through intelligent insights and actions. That’s why they call it Customer Relationship Magic.”

Immediately when using the product for the first time, Attio syncs with a business’ email and calendar systems to create a full global view of every relationship a business has. This automatically includes complete detailed profiles, with a timeline of interactions and conversations, intelligence on the strength of each relationship and enriched with hundreds of extra data points. Attio also allows for easy integration of data from other sources through developer-friendly APIs and first-party integrations.

Teams can then sort and filter millions of customer records in milliseconds. Users have the freedom to use that data to build highly customizable workflows for virtually any industry or scenario – pulling from a library of templates or using a blank canvas to start from scratch. The flexibility of Attio’s data model and architecture means users can adapt and change it rapidly on the fly for any use case, seamlessly scaling with a company as it grows.

“Attio is unlike any CRM we’ve ever encountered. It’s flexible, customizable and truly multiplayer,” said Alon Bartur, co-founder and CEO of early-stage startup Dopt, an Attio customer. “It has played a crucial role in helping us build and scale our go-to-market engine. From tackling sales pipelines to customer success, onboarding and everything in between, it constantly evolves with us as our business grows and has become an indispensable part of our technology stack.”

“From the moment we first learned about Attio, we knew right away that it had massive potential to transform how we manage customer relationships,” said Daniel Waterhouse, general partner at Balderton Capital. “It’s been incredible to see how much the product has evolved since our last investment. Attio’s combination of an amazing UX and powerful data architecture is something truly unique in the market. We believe in their team and vision to build the future of CRM.”

“With Attio, teams can leverage the flexibility and customization of a no-code tool while still getting all the power and features you’d expect from a CRM with a potent data structure to organize your relationships,” said Ricardo Sequerra, partner at Point Nine. “We’re incredibly impressed with the product’s rapid evolution and are excited to see Attio become generally available and work towards their vision of reinventing CRM.”

Availability

Attio is now generally available. To get started, go to https://attio.com.

About Attio

Attio is the CRM of the future. Real-time, completely customizable and intuitively collaborative, Attio’s powerful data model and next-generation architecture allows businesses of all sizes and at all stages to rapidly build the exact CRM they need. To learn what Attio can do for you, visit https://attio.com.

Logo: https://mma.prnewswire.com/media/2013990/Attio_Logo.jpg

SOURCE ATTIO LIMITED

Ballantyne is the co-founder and former chief scientific officer of Aldevron, a leading manufacturer of plasmids and other biologicals

BOSTON, March 2, 2023 — The co-founder of Aldevron, Dr. John Ballantyne, has invested $3M in CureLab Oncology and CureLab Veterinary. The two sister companies have developed an anti-cancer and anti-inflammatory drug that was contract-manufactured by Aldevron at the time Dr. Ballantyne served there as chief scientific officer. The investment positions both companies to attain the R&D milestones needed to secure additional rounds of funding.

Both CureLab Oncology and CureLab Veterinary are developing therapies that employ plasmids (circular DNA encoding a gene called p62/SQSTM1). CureLab Oncology is applying the p62 plasmid to treat human cancers. Following impressive clinical data presented at the European Society for Medical Oncology Congress in Paris, and the considerable ongoing progress of the company’s clinical studies, the funds will enable CureLab Oncology to ramp up toward FDA-monitored clinical trials for triple-negative breast cancer and platinum-resistant ovarian cancer in 2023.

“I have been observing the CureLab journey since Aldevron produced the very first batch of their product. I have witnessed the CureLab team growing and evolving, obtaining patent protection around the world, and keeping an eye on their pre-clinical and clinical progress. The team and the strength of their recent clinical data is what made me want to invest,” said Dr. John Ballantyne.

“Distributing Dr. Ballantyne’s investment among the two companies will greatly reduce the R&D risks for both CureLab Oncology and CureLab Veterinary,” said Dr. Alexander Shneider, CEO of CureLab Oncology.

The research activities of the two CureLab sister companies are highly synergistic. The data obtained in real-life veterinary settings, in pets, serves as a much stronger predictor for human clinical trials than experiments conducted on laboratory animals. For example, if CureLab Veterinary demonstrates that the product is effective in the treatment of canine osteoarthritis or inflammatory bowel syndrome, both of which are highly prevalent among dogs, CureLab Oncology could extend its clinical programs to treat these pathologies.

For the treatment of domestic animals, CureLab Veterinary received positive clinical results in 10 out of 11 dogs diagnosed with breast cancer. The company is looking to take its patented p62 plasmid technology through the USDA-CVB process with a view to marketing new anti-cancer and anti-inflammatory technologies for use by veterinarians.  

“As an industry leader in both thought and action, I am pleased that John has decided to support our efforts to bring innovative animal technology through the US approval process,” said Robert Devlin, president of CureLab Veterinary. “Through his generous support, we hope to help many animals and bring joy to pet owners worldwide.”

CureLab Veterinary is currently engaged in a crowdfunding effort with Netcapital.

About Elenagen

CureLab’s lead investigational compound is code-named Elenagen, an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1. In animal studies and Phase I/II human trials conducted ex-US, Elenagen demonstrated promise in reversing tumor grade, changing the tumor microenvironment, and enhancing the anti-cancer effects of chemotherapy. Experimental results also indicate mitigation of chronic inflammation and stimulation of an immune response to the tumor.

About CureLab Veterinary

Today, our four-legged family members are living longer than ever. Unfortunately, with this longer lifespan, our furry friends now are experiencing many of the same cancers and diseases due to chronic inflammation as their pet parents. CureLab Veterinary, a sister company of CureLab Oncology, is dedicated to bringing advanced therapies to treat cancer and inflammatory diseases to support better pet health and longevity. To learn more, visit curelabveterinary.com.

About CureLab Oncology

CureLab Oncology Inc. is a pre-IPO, clinical-stage immuno-oncology biotech company headquartered in the greater Boston area, Massachusetts. CureLab is dedicated to advancing new and safer therapeutics for solid tumors and other oncology and inflammatory indications. To learn more, visit curelab.com.

Media contact:
Tim Cox, ZingPR, [email protected]

SOURCE CureLab Oncology Inc.